Contents

• Foreword
• Index of conditions
• Executive summary
• 1. Introduction
  • National Blood Agreement
  • Governance arrangements for the supply and management of blood products in Australia
  • Availability of intravenous immunoglobulin in Australia
  • Intravenous Immunoglobulin Standing Offer
• 2. Production of normal immunoglobulins
  • Plasma fractionation
  • Product safety and regulation
  • Virus and prion removal
  • Intravenous immunoglobulin products in Australia
• 3. Intravenous immunoglobulin supply and demand
  • International
  • Domestic
  • World trends
  • IVIg demand management
• 4. Development and maintenance of the Criteria
  • Development of first edition
  • 2008 clarification process
  • 2010–11 Criteria Review
  • Assessment of evidence
  • Condition proforma
  • Replacement and immunomodulation therapy
  • Dosing
  • Research priorities
  • Maintenance
• 5. Conditions for which IVIg has an established therapeutic role
• 6. Conditions for which IVIg has an emerging therapeutic role
• 7. Conditions for which IVIg use is in exceptional circumstances only
• 8. Conditions for which IVIg use is not supported
• Acronyms and abbreviations
• Glossary of terms
• Bibliography
• Appendix A: Funding policy statement
• Appendix B: National Stewardship Expectations
• Appendix C: Development of the Criteria for the clinical use of IVIg in Australia (First Edition)
• Appendix D: 2010–11 Criteria Review
• Appendix E: Alphabetical index of conditions
• Index
• List of figures
• List of tables
• Index
• List of figures
  • Figure 1 Plasma sent to CSL Biotherapies Australia for fractionation
  • Figure 2 IVIg grams issued in Australia
  • Figure 3 Australian IVIg issued in g/1000 head of population
• List of tables
  • Table 1 Level of evidence categories
  • Table 2 Conditions for which IVIg has an established therapeutic role as immunoglobulin-replacement therapy
  • Table 3 Conditions for which IVIg has an established therapeutic role as immunomodulation therapy
  • Table 4 Conditions for which IVIg has an emerging therapeutic role as immunoglobulin replacement therapy
  • Table 5 Conditions for which IVIg has an emerging therapeutic role as immunomodulation therapy
  • Table 6 Conditions for which IVIg is used as immunoglobulin replacement therapy in exceptional circumstances
  • Table 7 Conditions for which IVIg is used in immunomodulation therapy in exceptional circumstances
  • Table 8 Conditions for which IVIg use is not supported